

-112-

**What is claimed is:**

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding IL-1 receptor-associated kinase-1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding IL-1 receptor-associated kinase-1 and inhibits the expression of IL-1 receptor-associated kinase-1.

2. The compound of claim 1 which is an antisense oligonucleotide.

3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding IL-1 receptor-associated kinase-1.

11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

-113-

12. The composition of claim 11 further comprising a colloidal dispersion system.

13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of IL-1 receptor-associated kinase-1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of IL-1 receptor-associated kinase-1 is inhibited.

15. A method of treating an animal having a disease or condition associated with IL-1 receptor-associated kinase-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of IL-1 receptor-associated kinase-1 is inhibited.

16. The method of claim 15 wherein the disease or condition is a hyperproliferative disorder.

17. The method of claim 16 wherein the hyperproliferative disorder is cancer.

18. The method of claim 15 wherein the disease or condition is an autoimmune disorder.

19. The method of claim 15 wherein the disease or condition is inflammation.

20. The method of claim 15 wherein the disease or condition involves bone metabolism.